In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

CLICK HERE FOR CME CREDIT

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology Chairman of the Department of Cardiology Heartcenter of the University Medical Center Nijmegen, The Netherlands